• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMVP alert in real time by email
    SC 13G 1 pmvp13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

    PMV Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, $0.00001 par value per share
    (Title of Class of Securities)
     
    69353Y103
    (CUSIP Number)
     
     December 6, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     3,269,907
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
      3,269,907
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
      3,269,907
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     6.3%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     

    Item 1(a). Name of Issuer:

     PMV Pharmaceuticals, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:
     

    400 Alexander Park Drive, Suite 301
    Princeton, NJ

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar, Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common stock, par value $0.00001
     
    Item 2(e). CUSIP Number:

     69353Y103


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 3,269,907


    (b) Percent of class: 6.3


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote:0


    (ii) Shared power to vote or to direct the vote: 3,269,907

      (iii) Sole power to dispose or to direct the disposition of:0

      (iv) Shared power to dispose or to direct the disposition of: 3,269,907
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

          n/a
      
         n

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: December 12, 2024
     
     
    BML CAPIITAL MANAGEMENT, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

    Get the next $PMVP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMVP

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Perform → Outperform
    Oppenheimer
    5/13/2024$6.00Buy
    Craig Hallum
    4/12/2024$5.00Buy
    Jefferies
    12/27/2023$7.00Buy
    Ladenburg Thalmann
    3/2/2022$30.00Perform → Outperform
    Oppenheimer
    3/2/2022Perform → Outperform
    Oppenheimer
    9/22/2021$35.00 → $43.00Neutral → Buy
    Goldman Sachs
    8/19/2021Perform
    Oppenheimer
    More analyst ratings

    $PMVP
    SEC Filings

    View All

    SEC Form 144 filed by PMV Pharmaceuticals Inc.

    144 - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    9/10/25 6:50:45 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - PMV Pharmaceuticals, Inc. (0001699382) (Filer)

    9/10/25 12:04:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PMV Pharmaceuticals Inc.

    SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    8/14/25 4:02:29 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

    PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR) observed among 97 evaluable patients across all cohorts with a median duration of response of 6.2 months43% ORR observed among 44 evaluable patients in ovarian cancer cohort with a median duration of response of 7.6 monthsRezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027Company to host investor webinar at 8:00 AM ET today to review Phase 2 interim clinical data PRINCETON

    9/10/25 7:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

    PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis   Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026 PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June

    8/7/25 8:42:03 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

    PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings. TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA Date: Tuesday, May 27, 2025Time: 11:30 AM EDT Jefferies Global Healthcare Conference Date: Thursday, June 5, 2025Time: 3:45 PM E

    5/23/25 4:05:00 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PMV Pharmaceuticals upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded PMV Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

    11/8/24 7:58:24 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on PMV Pharmaceuticals with a new price target

    Craig Hallum initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    5/13/24 8:31:58 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on PMV Pharmaceuticals with a new price target

    Jefferies initiated coverage of PMV Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    4/12/24 7:35:19 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc sold $900,000 worth of shares (500,000 units at $1.80) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    9/12/25 5:09:08 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel & COO Ticktin Robert sold $24,651 worth of shares (23,151 units at $1.06), decreasing direct ownership by 19% to 98,695 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:51:53 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Jalota Deepika sold $35,198 worth of shares (33,065 units at $1.06), decreasing direct ownership by 27% to 89,959 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    7/3/25 7:50:11 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    11/14/24 12:24:48 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PMV Pharmaceuticals Inc.

    SC 13G/A - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    7/8/24 4:32:39 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMVP
    Leadership Updates

    Live Leadership Updates

    View All

    PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

    CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotech leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is stepping down from the Board. The Board changes are effective immediately. "We are thrilled to welcome Carol to our Board. She is a recognized industry leader with a stellar track record of creating value. Her capabilities in

    11/4/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

    Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutationStrong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021 CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights. "We expect that 2022 will be another pr

    3/1/22 7:15:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMV Pharma Announces Changes to its Board of Directors

    CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV's Board. "Peter has been an invaluable member of the Board during a period of substantial growth and key successes, including completion of our IPO as well as entry of our lead candidate, PC14586, into the clinic," said David Mack, Ph.D., President and Chief Executive Officer of PMV. "On behalf o

    1/6/22 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care